Bol, Kalijn F.
Schreibelt, Gerty http://orcid.org/0000-0002-0156-8365
Bloemendal, Martine
van Willigen, Wouter W.
Hins-de Bree, Simone
de Goede, Anna L.
de Boer, Annemiek J.
Bos, Kevin J. H.
Duiveman-de Boer, Tjitske
Olde Nordkamp, Michel A. M.
van Oorschot, Tom G. M.
Popelier, Carlijn J.
Pots, Jeanne M.
Scharenborg, Nicole M.
van de Rakt, Mandy W. M. M.
de Ruiter, Valeska
van Meeteren, Wilmy S.
van Rossum, Michelle M.
Croockewit, Sandra J.
Koeneman, Bouke J. http://orcid.org/0000-0002-7224-1036
Creemers, Jeroen H. A. http://orcid.org/0000-0003-0371-8416
Wortel, Inge M. N. http://orcid.org/0000-0003-3362-5229
Angerer, Caroline
Brüning, Mareke
Petry, Katja
Dzionek, Andrzej
van der Veldt, Astrid A.
van Grünhagen, Dirk J. http://orcid.org/0000-0001-8293-6002
Werner, Johanna E. M.
Bonenkamp, Johannes J.
Haanen, John B. A. G. http://orcid.org/0000-0001-5884-7704
Boers-Sonderen, Marye J.
Koornstra, Rutger H. T.
Boomsma, Martijn F.
Aarntzen, Erik H. J.
Gotthardt, Martin
Nagarajah, James
de Witte, Theo J. M. http://orcid.org/0000-0001-5897-4287
Figdor, Carl G. http://orcid.org/0000-0002-2366-9212
de Wilt, Johannes H. W. http://orcid.org/0000-0001-6773-9668
Textor, Johannes http://orcid.org/0000-0002-0459-9458
de Groot, Jan Willem B.
Gerritsen, Winald R. http://orcid.org/0000-0003-1110-9119
de Vries, I. Jolanda M. http://orcid.org/0000-0002-8653-4040
Article History
Received: 9 May 2023
Accepted: 22 January 2024
First Online: 23 February 2024
Competing interests
: K.F.B.: consultancy fees (all paid to institute) from MSD and Pierre Fabre. A.A.v.d.V.: consultancy fees (all paid to institute) from BMS, MSD, Pierre Fabre, Merck, Pfizer, Novartis, Sanofi, Ipsen, Eisai, Roche. CA/MBr/KP/AD: employees of Miltenyi Biotec. J.W.B.d.G.: received personal fees outside the submitted work from Bristol-Myers Squibb, Roche, Pierre Fabre, Servier, MSD, and Novartis. J.B.A.G.H.: advisory relationships with Amgen, AstraZeneca, Bayer, Bristol-Myers Squibb, Celsius Therapeutics, GSK, Immunocore, Ipsen, MSD, Merck Serono, Novartis, Neon Therapeutics, Pfizer, Roche/Genentech, Sanofi, and Seattle Genetics and has received research grants not related to this paper from Novartis, BMS, MSD, and Neon Therapeutics. W.R.G.: speaker fees from MSD; advisory role (institutional) for Bristol-Myers Squibb and Bayer; research grants (institutional) from Astellas, Bayer, Janssen-Cilag, MSD. The remaining authors declare no competing interests.